Belgian biotech Dualyx enters Treg field with $44M for 2024 clinical entry
A young Belgian biotech aims to enter the clinic next year with a new Treg for autoimmune diseases, and now has $44 million in financing to do so.
The Series A will help Dualyx take its first Treg candidate, DT-001, into a Phase I study in the second half of 2024, CEO Wouter Verhoeven told Endpoints News on Monday. Their first program is an antibody going after TNF receptor 2, an immunosuppressive and “key immune modulator,” Verhoeven said, and they’ve yet to choose which autoimmune indications it will go after first.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.